

Functional Virus-Based Polymer–Protein Nanoparticles by Atom Transfer Radical Polymerization

Jonathan K. Pokorski,[†] Kurt Breitenkamp,[†] Lars O. Liepold,[‡] Shefah Qazi,[‡] and M.G. Finn^{*,†}[†]Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, United States[‡]Department of Chemistry, Center for BioInspired Nanomaterials, Montana State University, Bozeman, Montana 59717, United States

S Supporting Information

ABSTRACT: Viruses and virus-like particles (VLPs) are useful tools in biomedical research. Their defined structural attributes make them attractive platforms for engineered interactions over large molecular surface areas. In this report, we describe the use of VLPs as multivalent macroinitiators for atom transfer radical polymerization. The introduction of chemically reactive monomers during polymerization provides a robust platform for post-synthetic modification via the copper-catalyzed azide–alkyne cycloaddition reaction. These results provide the basis to construct nanoparticle delivery vehicles and imaging agents using protein–polymer conjugates.

Synthetic polymers are chemically diverse in terms of their size and composition and have long been used for the display of multiple copies of functional units. In contrast to their synthetic counterparts, biopolymers such as viruses and virus-like particles (VLPs) exhibit unique qualities of monodispersity and chemical regularity, allowing for the precise, periodic chemical functionalization of capsid structures.¹ VLPs can be both genetically² and chemically^{1b} modified to alter or introduce functionality and tailor biological functions. The combination of these two types of multivalent structures may prove advantageous in situations requiring organic nanoparticles with defined structural attributes.

Synthetic polymer nanoparticles prepared by emulsion, nanoprecipitation, self-assembly, or layer-by-layer techniques have been widely studied as delivery vehicles.³ Their potential advantages include high drug-loading capacities, ability to improve drug solubility, and the ready introduction of ligands for targeted delivery.⁴ However, the production of polymeric nanoparticles with precise structural homogeneity remains a challenge to the field.⁵ The use of biomolecular platforms is an attractive approach toward this end, and many examples exist of the modification of viral and non-viral protein structures with synthetic polymers using “grafting to” approaches.⁶ In contrast, there are few examples of the use of protein nanoparticles as multivalent macroinitiators for polymerization,⁷ and none using viruses.⁸

We describe here the polymerization of oligo(ethylene glycol)-methacrylate (**6**, OEGMA) and its azido-functionalized analogue (**7**, OEGMA-N₃) directly from the outer surface of the bacteriophage Q β VLP by atom transfer radical polymerization (ATRP). ATRP and other controlled radical polymerization

techniques have previously been used to prepare well-defined polymer–protein hybrid structures that maintain their biological functions while gaining improved pharmacokinetic properties.⁹ We expected ATRP to provide polymers with narrow molecular weight distributions, yielding structurally uniform hybrid protein–polymer nanoparticles from the monodisperse viral platform.

ATRP initiators were installed on the surface of Q β using a two-step “click” protocol (Figure 1), which would allow other functional units to be installed at the same time, if desired. First, *N*-hydroxysuccinimide **3** was used to attach an azide group to $\sim 180 \pm 30$ of the 720 surface-accessible amine groups of the particle (a value that is controlled by the selection of reaction conditions for this step and determined experimentally by mass spectrometry analysis of the denatured protein after modification). The resulting azido particle **3** was then functionalized with a triglyme-based ATRP initiator (**4**) by copper-catalyzed azide–alkyne cycloaddition (CuAAC) to form Q β macroinitiator **5**.¹⁰ Polymers were grown from the multivalent initiator using a 2,2'-bipyridine/CuBr/CuBr₂ catalyst system that was previously shown to yield high-molecular-weight polymers grafted from protein-based initiators in water.¹¹ A degassed, aqueous copper solution (0.1 mM final concentration) was added to a solution of particle **3** and the commercially available monomer **6** or **7** (final concentrations, 1 mg/mL (0.4 μ M) in VLP and 72 mM in monomer). After overnight room-temperature reactions under nitrogen, the polymerizations were terminated by exposure to air and addition of EDTA. The resulting protein–polymer conjugates were purified from the small-molecule reactants by sucrose gradient centrifugation and ultracentrifugation.

Size exclusion chromatography (SEC) and dynamic light scattering (DLS) were used to determine changes in particle size following ATRP. The former (Figure 2A) showed a shift in elution volume from ~ 12 min for unmodified Q β particles to 9.5 min for the significantly larger poly(OEGMA)-coated product. A similar shift was seen in electrophoretic mobility when the particles were analyzed on a native agarose gel, where polymer-coated particles remained near the baseline, a significant retardation compared to particle **5** (Figure 2D). DLS measurements (Figure 2E,F) confirmed the increase in particle hydrodynamic radius from 14 nm (Q β wild-type) to ~ 24 nm for the polymer-coated particles, with a narrow size distribution (polydispersity = 18%). The virus capsids, when visualized by TEM, were shown to remain intact following ATRP (Figure 2B,C).

Received: April 10, 2011

Published: May 31, 2011




Figure 1. Preparation of the $Q\beta$ VLP macroinitiator and polymerization from its surface.




Figure 2. Characterization of $Q\beta$ -polymer particles. (A) Size exclusion chromatographs. (B,C) Transmission electron micrographs of poly(OEGMA)- and poly(OEGMA- N_3)-coated particles (8 and 9, respectively); scale bar = 200 nm. (D) Non-denaturing agarose gel stained with ethidium bromide: lane 1, $Q\beta$ macroinitiator (5); lane 2, $Q\beta$ -poly(OEGMA) (8); lane 3, $Q\beta$ -poly(OEGMA- N_3) (9). (E,F) DLS histograms of 8 and 9, respectively.

ATRP provides a tertiary bromide at the terminus of each growing polymer chain, which is amenable to further transformation.¹² As shown in Figure 3, we reacted particle 8, which does not contain side-chain azide functionality, with a large molar excess of sodium azide in a water:DMSO mixture to substitute azide for bromide at the particle periphery. The resulting intermediate was then reacted with AlexaFluor488-alkyne under standard CuAAC bioconjugation conditions. Following sucrose gradient purification, the fluorescent particles were found to bear an average of ~ 20 dye molecules per particle by comparing Alexa UV absorbance (495 nm) versus total protein concentration (as measured by Bradford assay). No observable dye labeling occurred when 8 was subjected directly to CuAAC prior to sodium azide treatment, suggesting that no accessible azides remained following CuAAC to particle 3. The labeling of only 20 chains on a particle that started with 180 potential initiation sites suggests that either polymer initiation is strongly inhibited by previously initiated chains or that azide substitution and click cycloaddition reactions are inhibited by the presence of adjacent chains attached to the particle surface. Given the high efficiency of both azide nucleophilic attack and CuAAC coupling, we suspect that the former explanation is more likely. This issue will be studied further in upcoming experiments. We




Figure 3. End labeling of $Q\beta$ -poly(OEGMA) (8). For the structure of 11, see Figure 4.




Figure 4. Conjugation to polymer side chains. (A) CuAAC reaction to append functionality to 9. (B) UV illumination of sucrose gradient following CuAAC between 9 and 11 (upper band, unreacted 11; lower band, particle 14). (C) Conjugation of Gd-DOTA complex 12 to azide-functionalized capsid 3.

expect that the method of post-polymerization functionalization and bioconjugation described here will prove especially useful in attaching functional biomolecules such as cell targeting groups, cell penetrating peptides, or diagnostic agents.

The azido-functionalized oligo(ethylene glycol)-methacrylate, OEGMA- N_3 (7), also served as a competent monomer, allowing for a greater degree of post-polymerization functionalization while retaining PEG-like biocompatibility.¹³ The polymerization of 7 proceeded in the same manner as 6 (Figure 1), yielding hybrid $Q\beta$ -poly(OEGMA- N_3) particle 9 with properties very similar to those of the poly(OEGMA)-coated 8: ~ 10 nm increase in radius, narrow size distribution, and dramatically different electrophoretic mobility (Figure 2A,C,D,F).

To demonstrate the reactivity of poly(OEGMA- N_3) grafts, 9 was reacted with alkyne-substituted AlexaFluor488 dye 11 under CuAAC conditions (Figure 4A). Sucrose gradient centrifugation revealed an intensely colored green band, indicating a successful “click” reaction (Figure 4B). The potential sensitivity of the molar absorptivity of these dyes to their molecular environment made quantification of the coupling efficiency at high dye loadings impossible by absorbance measurements. The same reaction was therefore performed with gadolinium complex 11, and the coupling result assayed by quantitation of Gd by inductively coupled plasma optical emission spectroscopy (ICP-OES).¹⁴ Loading values of 500–650 Gd complexes per particle were routinely found for reactions with different samples of 9.

Nanoparticles bearing Gd complexes have attracted substantial interest as magnetic resonance imaging agents due to benefits anticipated for their large size (slowing rotational relaxation

Table 1. T1 Relaxivities ($\text{mM}^{-1} \text{s}^{-1}$) for Derivatized Virus-like Particles


sample	Gd/VLP	relaxivity per Gd (per VLP)	
		60 MHz	90 MHz
15	610	11.63 (7092)	10.12 (6174)
17	350	10.7 (3750)	11.64 (4075)

rates) and high Gd loading capacities. Several variations using VLPs have been reported.¹⁵ We had earlier described the direct attachment of Gd(DOTA)-alkyne complex **12** to azide-derivatized particle **3** and the magnetic resonance behavior of the resulting conjugate **17**.¹⁴ Examination of the $Q\beta$ -polymer-Gd particle **15** found a relaxivity on a per Gd basis similar to that of **17** at two different Larmor frequencies (Table 1; approximately double the value of the Gd complex alone), suggesting that the polymer backbone does not impart additional conformational rigidity to the complexes or restrict access to water. The per particle relaxivity of **15** ($7092 \text{ mM}^{-1} \text{s}^{-1}$), however, compares favorably to examples reported in the literature involving the covalent attachment of commercially available Gd reagents to virus particles.^{15b-d}

The multiple attachment points offered by the azide groups of polymer-decorated particle **9** may also be used to tether a releasable drug cargo. It has been reported that nanoparticles of $\sim 25 \text{ nm}$ radius are optimal for internalization via endocytotic pathways.¹⁶ The relatively acidic environments of endosomal and lysosomal compartments (pH 4.5–5.5) is most often used as the trigger for drug release, with hydrazones being a popular motif.¹⁷ Accordingly, we prepared a “clickable” doxorubicin hydrazone **13** for conjugation to the $Q\beta$ -polyazide **9** (Figure 4A). Because **13** has poorer aqueous solubility than the Gd complex, fewer doxorubicin (Dox) molecules were attached, an average of 150 per particle ($\sim 3 \text{ wt } \%$), determined by measuring Dox concentrations spectrophotometrically ($\lambda_{\text{abs}} = 490 \text{ nm}$) and comparing these to protein concentrations obtained by Bradford assay.¹⁸ The resulting particles **16** remained intact, with a narrow size distribution (by DLS, radius = 22.7 nm , 14% polydispersity). This stands in contrast to the conjugation of **13** directly to particle **3**, which led to degradation of the capsid structure and precipitation of the protein, as occasionally happens with hydrophobic or polyaromatic molecules.

The pH sensitivity of the Dox-conjugated particle **16** was assayed by fluorescence spectroscopy. The fluorescence of the Dox chromophores on **16** is known to be quenched at high local concentrations,¹⁹ allowing us to monitor the release of the drug ($\lambda_{\text{ex}} = 480 \text{ nm}$; $\lambda_{\text{em}} = 598 \text{ nm}$) from the conjugate into solution at pH 7.4 and 5.5.²⁰ The maximum fluorescence was reached after $\sim 2 \text{ h}$ at pH 5.5, while no fluorescence increase was observed after 12 h for the particles incubated at pH 7.4 (Figure 5A), consistent with the expected properties of the hydrazone linkage.

The pH-sensitive, Dox-conjugated particle **16** was also found to be cytotoxic to HeLa cells, a cervical cancer cell line that is sensitive to treatment with Dox.²¹ Cells were incubated with varying concentrations of **16** or appropriate controls for 8 h in pH 7 buffer (in which no cleavage of Dox from the particle occurs) and were assayed for cell viability the following day using the MTT assay. Polymer conjugate **16** exhibited a cytotoxicity profile similar to that of free Dox (in terms of overall Dox concentrations) under the same assay conditions (Figure 5B), indicating that the particles are internalized and release their payload to effect cell

**Figure 5.** (A) *In vitro* release profile of doxorubicin from particle **16** at pH 7.4 and 5.5 (MES = 2(*N*-morpholino)ethanesulfonic acid buffer; PBS = phosphate-buffered saline). (B) MTT assay for cell viability after treatment with the indicated agents; see text.

death. The cells showed no significant signs of toxicity when exposed to unloaded particles (**9**) at the concentration range used with **16** (Supporting Information).

In summary, we have shown that VLPs derived from the bacteriophage $Q\beta$ can serve as a platform for controlled radical polymerization to produce polymer-coated protein nanoparticles. The size and surface properties of $Q\beta$ can be significantly altered through ATRP while still retaining the low polydispersities associated with VLPs. Furthermore, the polymer-coated particles are accessible to bioconjugation at both the chain termini and suitably derivatized polymer side chains. The platform allows for both conjugation of small-molecule imaging agents and chemotherapeutics. Future studies will focus on varying the nature and properties of the polymers grown from capsid surfaces and on further exploration of this platform for development of targeted drug delivery and imaging agents.

■ ASSOCIATED CONTENT

S Supporting Information. Detailed procedures for all chemical transformations and cell-based assays. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author
mgfinn@scripps.edu

■ ACKNOWLEDGMENT

This work was supported by the National Institutes of Health (CA112075, RR021886, R21EB005364) and by a Pathway to Independence Award (K99EB011530) to J.K.P. We thank Prof. Trevor Douglas for helpful discussions and Dr. Burkhardt Laufer for the synthesis of Gd complex **12**.

■ REFERENCES

- (a) Steinmetz, N. F. *Nanomedicine: Nanotechnol., Biol., Med.* **2010**, *6*, 634–641. (b) Strable, E.; Finn, M. G. *Curr. Top. Microbiol. Immunol.* **2009**, *327*, 1–21.
- Brown, S.; Fiedler, J.; Finn, M. G. *Biochemistry* **2009**, *48*, 11155–11157.
- Mora-Huertas, C. E.; Fessi, H.; Elaissari, A. *Int. J. Pharm.* **2010**, *385*, 113–142.
- Petros, R. A.; Desimone, J. M. *Nat. Rev. Drug Discovery* **2010**, *9*, 615–627.
- Good control over size has been achieved in many systems, including polymer nanoparticles: (a) Duan, H.; Kuang, M.; Zhang, G.; Wang, D.; Kurth, D. G.; Möhwald, H. *Langmuir* **2005**, *21*, 11495–11499. (b) Yanagishita, T.; Fujimura, R.; Nishio, K.; Masuda, H. *Langmuir*

2009, 26, 1516–1519. (c) An, S. Y.; Bui, M.-P. N.; Nam, Y. J.; Han, K. N.; Li, C. A.; Choo, J.; Lee, E. K.; Katoh, S.; Kumada, Y.; Seong, G. H. *J. Colloid Interface Sci.* **2009**, 331, 98–103.

(6) (a) Kovacs, E. W.; Hooker, J. M.; Romanini, D. W.; Holder, P. G.; Berry, K. E.; Francis, M. B. *Bioconjugate Chem.* **2007**, 18, 1140–1147. (b) Brunel, F. M.; Lewis, J. D.; Destito, G.; Steinmetz, N. F.; Manchester, M.; Stuhlmann, H.; Dawson, P. E. *Nano Lett.* **2010**, 10, 1093–1097. (c) Bruckman, M. A.; Kaur, G.; Lee, L. A.; Xie, F.; Sepulveda, J.; Breitenkamp, R.; Zhang, X.; Joralemon, M.; Russell, T. P.; Emrick, T.; Wang, Q. *ChemBioChem* **2008**, 9, 519–523. (d) Holder, P. G.; Finley, D. T.; Stephanopoulos, N.; Walton, R.; Clark, D. S.; Francis, M. B. *Langmuir* **2010**, 26, 17383–17388.

(7) (a) Hu, Y. X.; Samanta, D.; Parelkar, S. S.; Hong, S. W.; Wang, Q. A.; Russell, T. P.; Emrick, T. *Adv. Funct. Mater.* **2010**, 20, 3603–3612. (b) Zeng, Q.; Li, T.; Cash, B.; Li, S.; Xie, F.; Wang, Q. *Chem. Commun.* **2007**, 1453–1455. (c) Li, H.; Li, M.; Yu, X.; Bapat, A. P.; Sumerlin, B. S. *Polym. Chem.* **2011**, DOI 10.1039/c1py00031d.

(8) Many examples exist showing polymerization from the surfaces of polymer and metal nanoparticles. For examples, see: (a) Barbey, R.; Lavanant, L.; Paripovic, D.; Schuwer, N.; Sugnaux, C.; Tugulu, S.; Klok, H.-A. *Chem. Rev.* **2009**, 109, 5437–5527. (b) Zou, H.; Wu, S.; Shen, J. *Chem. Rev.* **2008**, 108, 3893–3957. For key examples, see: (c) Ali, A. M. I.; Mayes, A. G. *Macromolecules* **2010**, 43, 837–844. (d) Skaff, H.; Emrick, T. *Angew. Chem. Int. Ed.* **2004**, 43, 5383–5386. (e) Perruchot, C.; Khan, M. A.; Kamitsis, A.; Armes, S. P.; Von Werne, T.; Patten, T. E. *Langmuir* **2001**, 17, 4479–4481.

(9) (a) Heredia, K. L.; Bontempo, D.; Ly, T.; Byers, J. T.; Halstenberg, S.; Maynard, H. D. *J. Am. Chem. Soc.* **2005**, 127, 16955–16960. (b) Bontempo, D.; Maynard, H. D. *J. Am. Chem. Soc.* **2005**, 127, 6508–6509. (c) De, P.; Li, M.; Gondi, S. R.; Sumerlin, B. S. *J. Am. Chem. Soc.* **2008**, 130, 11288–11289. (d) Lele, B. S.; Murata, H.; Matyjaszewski, K.; Russell, A. J. *Biomacromolecules* **2005**, 6, 3380–3387.

(10) (a) Hong, V.; Presolski, S. I.; Ma, C.; Finn, M. G. *Angew. Chem. Int. Ed.* **2009**, 48, 9879–9883. (b) Control experiments showed that no degradation of or insertion into the tertiary bromide initiation site occurs under CuAAC reaction conditions.

(11) Peeler, J. C.; Woodman, B. F.; Averick, S.; Miyake-Stoner, S. J.; Stokes, A. L.; Hess, K. R.; Matyjaszewski, K.; Mehl, R. A. *J. Am. Chem. Soc.* **2010**, 132, 13575–13577.

(12) (a) Golas, P.; Tsarevsky, N.; Sumerlin, B.; Walker, L.; Matyjaszewski, K. *Aust. J. Chem.* **2007**, 60, 400–404. (b) Tsarevsky, N. V.; Sumerlin, B. S.; Matyjaszewski, K. *Macromolecules* **2005**, 38, 3558–3561.

(13) (a) Gao, W.; Liu, W.; Christensen, T.; Zalutsky, M.; Chilkoti, A. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, 107, 16432–16437. (b) Gao, W.; Liu, W.; Mackay, J. A.; Zalutsky, M. R.; Toone, E. J.; Chilkoti, A. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, 106, 15231–15236.

(14) Prasuhn, D. E.; Yeh, R. M.; Obenaus, A.; Manchester, M.; Finn, M. G. *Chem. Commun.* **2007**, 1269–1271.

(15) (a) Liepold, L. O.; Abedin, M. J.; Buckhouse, E. D.; Frank, J.; Young, M. J.; Douglas, T. *Nano Lett.* **2009**, 9, 4520–4526. (b) Liepold, L.; Anderson, S.; Willits, D.; Oltrogge, L.; Frank, J.; Douglas, T.; Young, M. *Magn. Reson. Med.* **2007**, 58, 871–879. (c) Hooker, J. M.; Datta, A.; Botta, M.; Raymond, K. N.; Francis, M. B. *Nano Lett.* **2007**, 7, 2207–2210. (d) Anderson, E. A.; Isaacman, S.; Peabody, D. S.; Wang, E. Y.; Canary, J. W.; Kirshenbaum, K. *Nano Lett.* **2006**, 6, 1160–1164.

(16) Zhang, S.; Li, J.; Lykotraftis, G.; Bao, G.; Suresh, S. *Adv. Mater.* **2009**, 21, 419–424.

(17) (a) De Jesus, O. L. P.; Ihre, H. R.; Gagne, L.; Frechet, J. M. J.; Szoka, F. C. *Bioconjugate Chem.* **2002**, 13, 453–461. (b) Bae, Y.; Fukushima, S.; Harada, A.; Kataoka, K. *Angew. Chem. Int. Ed.* **2003**, 42, 4640–4643. (c) Ulbrich, K.; Subr, V. *Adv. Drug Delivery Rev.* **2004**, 56, 1023–1050.

(18) Missirlis, D.; Kawamura, R.; Tirelli, N.; Hubbell, J. *Eur. J. Pharm. Sci.* **2006**, 29, 120–129.

(19) Mohan, P.; Rapoport, N. *Mol. Pharmaceutics* **2010**, 7, 1959–1973.

(20) (a) Ta, T.; Convertine, A. J.; Reyes, C. R.; Stayton, P. S.; Porter, T. M. *Biomacromolecules* **2010**, 11, 1915–1920. (b) Karukstis, K. K.; Thompson, E. H. Z.; Whiles, J. A.; Rosenfeld, R. J. *Biophys. Chem.* **1998**, 73, 249–263.

(21) Eichholtz-Wirth, H. *Br. J. Cancer* **1980**, 41, 886–891.